Literature DB >> 33530150

Hypertension in cancer patients treated with anti-angiogenic based regimens.

Yishay Wasserstrum1,2, Ran Kornowski1,2, Pia Raanani3,2, Avi Leader3,2, Oren Pasvolsky3,2, Zaza Iakobishvili4,5.   

Abstract

New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.

Entities:  

Keywords:  Cardiotoxicity; Hypertension; Tyrosine kinase inhibitor; VEGF; VEGF signal pathway inhibitors; VSP inhibitors; Vascular endothelial growth factor

Year:  2015        PMID： 33530150     DOI： 10.1186/s40959-015-0009-4

Source DB:  PubMed          Journal:  Cardiooncology        ISSN： 2057-3804


  116 in total

Review 1.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Sònia Tugues; Xiujuan Li; Laura Gualandi; Lena Claesson-Welsh
Journal:  Biochem J       Date:  2011-07-15       Impact factor: 3.857

Review 3.  VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.

Authors:  P Sapra Sharma; R Sharma; T Tyagi
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

4.  Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo.

Authors:  Ramona S Scotland; Melanie Madhani; Sharmila Chauhan; Salvador Moncada; Jørgen Andresen; Holger Nilsson; Adrian J Hobbs; Amrita Ahluwalia
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

Review 5.  Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress.

Authors:  Stephanie Lankhorst; Mariëtte H W Kappers; Joep H M van Esch; A H Jan Danser; Anton H van den Meiracker
Journal:  Antioxid Redox Signal       Date:  2013-04-03       Impact factor: 8.401

6.  Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.

Authors:  Brian Dreyfus; Hugh Kawabata; Andres Gomez
Journal:  Cancer Epidemiol       Date:  2012-12-12       Impact factor: 2.984

Review 7.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

8.  Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.

Authors:  Carie S Facemire; Andrew B Nixon; Robert Griffiths; Herbert Hurwitz; Thomas M Coffman
Journal:  Hypertension       Date:  2009-08-03       Impact factor: 10.190

9.  Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.

Authors:  Erica L Mayer; Susan M Dallabrida; Maria A Rupnick; Whitney M Redline; Keri Hannagan; Nesreen S Ismail; Harold J Burstein; Joshua A Beckman
Journal:  Hypertension       Date:  2011-04-11       Impact factor: 10.190

10.  Cancer, comorbidities, and health-related quality of life of older adults.

Authors:  Ashley Wilder Smith; Bryce B Reeve; Keith M Bellizzi; Linda C Harlan; Carrie N Klabunde; Marni Amsellem; Arlene S Bierman; Ron D Hays
Journal:  Health Care Financ Rev       Date:  2008
View more
  7 in total

1.  Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors.

Authors:  Sallie-Anne Pearson; Claire M Vajdic; Soojung Hong; Benjamin Daniels; Marina T van Leeuwen
Journal:  Discov Oncol       Date:  2022-01-20

2.  Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser.

Authors:  Erman Cilsal; Emine Alyamac Sukgen
Journal:  Cardiovasc J Afr       Date:  2020-01-13       Impact factor: 1.167

Review 3.  Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.

Authors:  Chris Plummer; Agnieszka Michael; Ghazia Shaikh; Michael Stewart; Lynn Buckley; Tracie Miles; Agnes Ograbek; Terry McCormack
Journal:  Br J Cancer       Date:  2019-06-11       Impact factor: 7.640

4.  Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.

Authors:  Sarah Waliany; Kristin L Sainani; Lesley S Park; Chiyuan Amy Zhang; Sandy Srinivas; Ronald M Witteles
Journal:  JACC CardioOncol       Date:  2019-09-24

Review 5.  Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.

Authors:  Anne Christine Kaae; Michael C Kreissl; Marcus Krüger; Manfred Infanger; Daniela Grimm; Markus Wehland
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

Review 6.  Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.

Authors:  Paula Jimenez-Fonseca
Journal:  Cancer Med       Date:  2022-10       Impact factor: 4.711

7.  Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.

Authors:  Iwona Baranowska; Olga Gawrys; Agnieszka Walkowska; Krzysztof H Olszynski; Luděk Červenka; John R Falck; Adeniyi M Adebesin; John D Imig; Elżbieta Kompanowska-Jezierska
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.